Key Findings From Recent Trials

Basic Cefixime Information

• INN (International Nonproprietary Name): not specified
• Brand Names Available In United Kingdom: not specified
• ATC Code: not specified
• Forms & Dosages: film-coated tablets (various strengths), oral suspension formulations, solutions for injection (where applicable in other products), suppositories and topical forms not specified for this INN
• Manufacturers In United Kingdom: not specified
• Registration Status In United Kingdom: not specified
• OTC / Rx Classification: Prescription (Rx) in most regions; may be OTC in specific formulations or dosages in some countries

Major 2022–2025 Studies

Which recent trials matter to prescribers and pharmacists?

Large observational surveillance from national reference laboratories across Europe and the UK between 2022 and 2024 tracked cefixime minimum inhibitory concentrations (MICs) in key pathogens.

Randomised and quasi‑randomised comparative trials examined oral cefixime regimens versus parenteral third‑generation cephalosporins for uncomplicated gonorrhoea and pragmatic community studies assessed cefixime for urinary tract infections and paediatric otitis media.

National public‑health reports such as UKHSA and European reference lab summaries contributed laboratory and clinical outcome data during this period.

Pharmacokinetic head‑to‑head studies quantified differences in peak serum concentrations between oral cefixime and parenteral ceftriaxone, explaining some clinical observations in high‑burden infections.

These large series and trials form the evidence base prompting recent guideline changes and prescribing cautions in the UK.

Main Outcomes

Surveillance consistently shows rising MICs and reduced susceptibility to cefixime among Neisseria gonorrhoeae isolates in many regions up to 2024.

Trials comparing single‑dose oral cefixime (commonly 400 mg) or divided dosing (200 mg twice daily) to intramuscular ceftriaxone demonstrated lower microbiological and clinical cure rates with cefixime for gonorrhoea.

For uncomplicated lower urinary tract infections and paediatric otitis media, pragmatic cohort studies through 2023 show acceptable clinical response where local susceptibility remains high.

However, the increasing prevalence of ESBL‑producing Escherichia coli in community isolates reduces the reliability of cefixime for empirical oral UTI therapy in many UK areas.

Consequently, national guidance has downgraded cefixime for gonorrhoea and recommends targeted rather than empirical use for community UTIs in high‑resistance settings.

Safety Observations

Across trials and surveillance programmes the safety profile of cefixime remains consistent with third‑generation cephalosporins.

Common adverse events reported were gastrointestinal symptoms, transient hepatic enzyme rises and cutaneous reactions.

Serious allergic reactions, including anaphylaxis and severe cutaneous adverse reactions, were rare but recorded.

Clostridioides difficile infection following broad‑spectrum antibiotic exposure continues to be an important safety consideration in both community and hospital settings.

Pharmacokinetic studies reported lower peak serum concentrations after oral cefixime compared with parenteral third‑generation cephalosporins, accounting for reduced efficacy in high‑load infections such as gonorrhoea.

Conclusions are drawn from national surveillance reports and peer‑reviewed comparative trials.

Clinical Mechanism Of Action

Layman’s Explanation

What does cefixime do in plain terms?

Cefixime is an oral third‑generation cephalosporin antibiotic that weakens the bacteria’s cell wall, stopping bacteria from surviving and allowing the immune system to clear the infection.

The medicine treats many respiratory and urinary infections and certain sexually transmitted infections when the causative bacteria are sensitive.

It is available as tablets and a paediatric suspension formulation for children who cannot swallow tablets.

Scientific Breakdown

How does cefixime work at a molecular level?

Cefixime binds to penicillin‑binding proteins (PBPs) on susceptible Gram‑negative and some Gram‑positive bacteria and inhibits the transpeptidation step of peptidoglycan synthesis.

This disruption of cell wall synthesis causes instability and bactericidal activity during bacterial growth phases.

Key pharmacokinetic points include an oral bioavailability of roughly 40–50% with some variability between patients and formulations.

Time to maximum concentration (Tmax) typically occurs around two to four hours after dosing, and plasma protein binding is approximately 65%.

Elimination is primarily renal with some biliary excretion, and the terminal half‑life supports once‑daily or twice‑daily dosing depending on indication and formulation.

Recognised resistance mechanisms include altered PBPs, production of beta‑lactamases such as ESBLs and AmpC, and changes in porin channels or efflux in Gram‑negative organisms.

Clinically, increased MICs correlate with reduced likelihood of cure, especially in infections with high bacterial loads such as gonorrhoea.

Mechanism and PK data align with regulatory monographs and pharmacology reviews.

Scope Of Approved And Off‑Label Use

United Kingdom Approvals

Which infections is cefixime licensed to treat in the UK?

Licensed indications in the UK for oral cefixime formulations commonly include uncomplicated urinary tract infections, acute otitis media and selected respiratory tract infections caused by susceptible organisms.

Paediatric oral suspension is often licensed for otitis media and pharyngitis in children where the pathogen is sensitive.

Historically cefixime had a licensed role for gonorrhoea but guideline updates have shifted first‑line therapy to parenteral ceftriaxone because of resistance and efficacy concerns.

Always consult the product SPC for brand‑specific licensed indications and age limits.

Notable Off‑Label Trends

Where is cefixime being used off‑label?

Off‑label use persists as oral step‑down therapy after an initial intravenous cephalosporin in selected mild‑to‑moderate infections when culture and sensitivity support the switch.

Clinicians may use cefixime for outpatient management of complicated urinary infections or for febrile neutropaenia as part of step‑down regimens when local protocols allow.

UK stewardship guidance discourages empirical cefixime for community UTIs in areas with high ESBL prevalence.

Special populations require attention: paediatric dosing is weight‑based and elderly patients need renal dosing adjustments and careful review of comorbidities.

Licensed uses and stewardship recommendations align with MHRA SPCs and national guidance.

Dosage Strategy

General Dosing

What dosing patterns are used for adults and children?

Typical adult regimens include 400 mg once daily or 200 mg twice daily for standard susceptible infections, with duration adapted to the infection site and severity.

Paediatric dosing for the oral suspension commonly follows weight bands, often around 8 mg/kg per day, divided or once daily depending on formulation and age.

In patients with renal impairment, dose reduction or extended dosing intervals are required for reduced creatinine clearance, and specialist advice is recommended for severe renal failure.

Always follow the SPC and local guidelines when selecting dose and duration.

Condition‑Specific Dosing

How long should treatment last for common infections?

Uncomplicated lower urinary tract infection: 400 mg once daily for three to seven days depending on severity and clinical response, and directed therapy based on culture is preferred.

Acute otitis media and community‑acquired pneumonia in children or adults: durations of five to ten days are typical, tailored by clinical course and age.

Uncomplicated gonorrhoea: single oral 400 mg doses historically used now show lower cure rates and are no longer routinely recommended as first‑line therapy.

For step‑down therapy after IV cephalosporin, ensure culture and sensitivity confirm suitability before switching to oral cefixime.

Dosage recommendations are aligned with SPC, BNF and stewardship guidance; always verify local recommendations before prescribing.

Safety Protocols

Contraindications

Who must not take cefixime?

Absolute contraindications are known hypersensitivity to cefixime, other cephalosporins, or severe beta‑lactam allergy.

Caution is needed for patients with a history of immediate‑type penicillin allergy due to potential cross‑reactivity; assessment should be individualised.

Use with specialist input in patients with severe hepatic failure, particularly when combined hepatic and renal dysfunction exists.

Adverse Effects

What side effects should patients and prescribers watch for?

Common adverse effects include gastrointestinal upset such as diarrhoea and nausea, mild transient hepatic enzyme elevations, and skin rash.

Serious but rare effects reported include anaphylaxis, severe cutaneous adverse reactions such as Stevens–Johnson syndrome or toxic epidermal necrolysis, and Clostridioides difficile infection following broad‑spectrum antibiotic exposure.

Haematological effects such as neutropaenia or thrombocytopenia are uncommon and generally reversible on stopping therapy.

Advise patients to stop the medicine and seek urgent review for rash, breathlessness, severe diarrhoea or other signs of severe reaction.

Baseline renal function testing is recommended in elderly or comorbid patients to guide dosing.

Interaction Mapping

Food Interactions

Do food and drink affect cefixime?

Taking cefixime with food may delay absorption and increase Tmax, but it does not substantially reduce clinical efficacy for most indications.

There are no strict food restrictions, and patients may be advised to take the dose with food if it improves tolerability or adherence.

Drug Combinations To Avoid

Which medicines need monitoring or avoidance?

Probenecid reduces renal excretion and can increase cefixime plasma levels; monitor for increased effects and toxicity if co‑prescribed.

Concurrent nephrotoxic agents such as aminoglycosides or high‑dose diuretics warrant renal function monitoring.

Beta‑lactam antibiotics can interact indirectly with oral anticoagulants; some beta‑lactams have been reported to raise INR, so monitor INR when warfarin or other VKAs are used concurrently.

Antacids containing aluminium or magnesium may reduce absorption of oral cephalosporins; separate doses by a few hours where possible.

Antibiotics can cause gastrointestinal upset and diarrhoea that may reduce the efficacy of oral contraceptives; counsel on additional contraception if diarrhoea occurs.

Patient Experience Analysis

Survey Data

What do patients say about taking cefixime?

Primary‑care and pharmacy surveys in the UK show good satisfaction with once‑daily oral dosing and convenience, particularly among caregivers using the paediatric suspension.

Common complaints include gastrointestinal upset and taste issues with the suspension in children.

Patients generally report symptom relief within 48–72 hours when the infecting organism is susceptible.

Forum Trends

What do online forums and NHS feedback reveal?

Online patient narratives reveal confusion between oral cefixime and injectable ceftriaxone, with many patients assuming injections are always stronger.

Patients report frustration with delays while waiting for culture results before targeted therapy can be started, which reflects stewardship-driven practice in the UK.

Adherence drivers identified include simple dosing schedules, clear patient information leaflets and accessible pharmacy counselling.

Distribution And Pricing Landscape

How is cefixime supplied and what does it cost?

In the UK, cefixime is supplied primarily through community pharmacies and hospital formularies for oral step‑down therapy.

Branded examples and generics are available, with tablets commonly provided in strengths that support 200 mg or 400 mg dosing and paediatric suspension supplied in 50–100 mL bottles.

Generic formulations are generally low cost, but prices vary by supplier and NHS tender arrangements.

Occasional shortages or supply constraints can cause temporary price increases or prompt alternative prescribing.

Global e‑commerce sources exist but importing prescription antibiotics without local prescriber oversight raises regulatory and authenticity concerns.

In our online pharmacy, cefixime is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Hospital procurement tends to prefer cost‑effective generics with secure supply chains to support stewardship and continuity of care.

Alternative Options

Comparison Table

Which antibiotics are commonly compared to cefixime?

Cefixime: oral third‑generation cephalosporin useful for step‑down and paediatric use, but with rising resistance for gonorrhoea and variable absorption.

Ceftriaxone: parenteral third‑generation cephalosporin with high efficacy for gonorrhoea and severe infections but requires IM or IV administration.

Amoxicillin/Clavulanate: broad community spectrum for some RTIs and UTIs but less reliable against resistant Gram‑negatives and ESBLs.

Nitrofurantoin: effective for uncomplicated lower UTIs with low systemic exposure; unsuitable for pyelonephritis.

Trimethoprim/Sulfamethoxazole and Fluoroquinolones: oral options with specific indications; resistance patterns and safety concerns (e.g., tendon injury, QT prolongation) limit their use.

Pros And Cons

Selecting an alternative depends on pathogen susceptibility, infection site, patient factors such as pregnancy or renal impairment, and stewardship goals.

For gonorrhoea, parenteral ceftriaxone remains preferred for effectiveness against resistant strains.

For uncomplicated lower UTI, nitrofurantoin is a reliable oral agent when the infection is limited to the bladder and nitrofurantoin is not contraindicated.

Discussion with local microbiology and review of susceptibility patterns is essential for informed antibiotic selection.

Regulatory Status

United Kingdom And EMA Perspective

How do regulators view cefixime now?

In the UK, cefixime products are authorised under MHRA‑approved SPCs for specified indications and age groups for each brand or generic.

Post‑Brexit the MHRA oversees licensing and periodic safety updates for products marketed in the UK.

National guideline bodies such as UKHSA and BASHH have updated clinical recommendations, reducing cefixime’s role for gonorrhoea due to increasing resistance and lower cure rates.

Suspected serious reactions are reported through the Yellow Card scheme and reviewed for any required SPC amendments.

Global Considerations

Globally some countries continue to list cefixime for limited first‑line indications, while WHO and many national STI guidelines favour parenteral ceftriaxone for gonorrhoea.

National practices differ depending on local resistance patterns and availability of parenteral therapy options.

Consolidated FAQ

Quick Answers To Common Queries

Is cefixime first‑line for gonorrhoea?

No. Current UK guidance prefers intramuscular ceftriaxone because of better cure rates, and cefixime is not recommended empirically.

Can I take cefixime with food?

Yes. Food may slightly delay absorption but is generally acceptable and can improve tolerability.

Is cefixime safe in pregnancy?

Many practitioners consider cefixime acceptable when clinically indicated in pregnancy, but consult obstetric guidance and the SPC before prescribing.

What if I miss a dose?

Take the missed dose as soon as remembered unless it is close to the next scheduled dose; do not double up doses.

How long to expect symptom relief?

Often 48–72 hours when the infecting pathogen is susceptible; seek review if there is no improvement or if symptoms worsen.

Visual Guide

Dose Charts And Patient Leaflets

Which visual aids help patients and clinicians?

Provide simple adult and paediatric dose charts by weight bands and a renal adjustment flowchart for quick reference in clinical practice.

Patient leaflets should list key warnings, administration advice, side effects to watch for and when to seek urgent care.

Infographic Concepts

PK Curve

Create a single‑dose 24‑hour concentration‑time graph to illustrate oral cefixime Tmax and lower Cmax compared with parenteral ceftriaxone.

Resistance Map

Use a regional UK susceptibility heatmap based on local laboratory data to guide empirical prescribing choices and stewardship decisions.

These visual aids improve adherence and support evidence‑based counselling for patients and prescribers.

Storage And Transport

How should cefixime be stored and transported?

Store tablets and suspensions at ambient room temperature below 25°C, protected from moisture and light unless the SPC for a specific brand indicates otherwise.

Reconstituted paediatric suspensions often require refrigeration or specific storage per the product label and should be discarded after the recommended period, frequently seven to fourteen days depending on formulation.

Adhere to Good Distribution Practice for transport and monitor temperature and humidity where required by the manufacturer.

Keep all medicines out of reach of children and follow secure prescription handling to avoid diversion.

Pharmacies should source products from MHRA‑compliant distributors and maintain batch recall procedures for quality events.

Guidelines For Proper Use

Prescriber Checklist

What should prescribers confirm before issuing cefixime?

Confirm the clinical indication and local susceptibility patterns before starting therapy.

Check allergy history, including penicillin or cephalosporin hypersensitivity, and assess renal function for dosing adjustments.

Consider alternatives for suspected ESBL organisms or severe systemic infections and document the clinical rationale in the record for stewardship audits.

Obtain cultures (urine, throat or genital swabs) before treatment where feasible to enable targeted therapy.

Patient Counselling Points

What should patients be told at the pharmacy or clinic?

Explain the dosing schedule and the total duration of therapy and advise on how to take the suspension to minimise taste issues.

Warn patients about common side effects such as diarrhoea and rash and instruct them to seek urgent review for breathlessness, severe rash or persistent watery diarrhoea.

Discuss infection control measures, partner notification for sexually transmitted infections and contraception advice if diarrhoea occurs during treatment.

Advise safe disposal of unused antibiotics and arrange follow‑up if there is no improvement within 48–72 hours or sooner if severe features develop.

Delivery Across United Kingdom

Trust And Practical Notes

How should clinicians and patients balance access with stewardship?

Prescribers should use local susceptibility data and national guidance to choose appropriate therapy and avoid empirical cefixime where resistance is likely.

Pharmacists should counsel patients on expected timelines for symptom relief and advise when to seek review for treatment failure or adverse events.

Report suspected serious adverse reactions through the Yellow Card scheme to support ongoing pharmacovigilance.

Where oral therapy is necessary, ensure culture‑guided selection and document rationale for off‑label or step‑down use for audit and stewardship purposes.

Final Practical Checklist

Quick summary to apply in practice.

• Check local resistance: confirm susceptibility before using cefixime for UTIs or STIs where possible.
• Review allergies: verify no severe beta‑lactam allergy and consider cross‑reactivity with penicillins.
• Adjust for renal function: calculate creatinine clearance for dosing decisions in elderly or comorbid patients.
• Provide patient information: give clear instructions, side‑effect warnings and follow‑up advice.